Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

697
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
697
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

89
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
89
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

61
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
61
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

523
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interpreting apparent differences among the major colchicine trials for cardiovascular prevention: a descriptive compatibility analysis.

American heart journal·2026
Same author

DOAC Score Among Patients Receiving Vitamin K Antagonists.

American heart journal·2026
Same author

Impact of Animal Assisted Therapy on Quality, Completeness, and Satisfaction in Pediatric Echocardiography.

Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography·2026
Same author

Patient-Centered Evaluation of Anticoagulation in Atrial Fibrillation.

NEJM evidence·2026
Same author

Comparative effectiveness of antidepressants for depression using EHRs from two health systems.

BMC psychiatry·2026
Same author

AI-Based Automation for Medication Reconciliation: Scoping Review.

Journal of medical Internet research·2026

Related Experiment Video

Updated: Jul 2, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.6K

Optimizing warfarin dosing for patients with atrial fibrillation using machine learning.

Jeremy Petch1,2,3,4, Walter Nelson5,6, Mary Wu7

  • 1Centre for Data Science and Digital Health, Hamilton Health Sciences, Hamilton, ON, Canada. petchj@hhsc.ca.

Scientific Reports
|February 24, 2024
PubMed
Summary

Deep reinforcement learning optimizes warfarin dosing for atrial fibrillation patients, improving time in therapeutic INR range and reducing adverse events. This AI approach enhances stroke prevention strategies globally.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K

Related Experiment Videos

Last Updated: Jul 2, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.6K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K

Area of Science:

  • Artificial Intelligence in Medicine
  • Pharmacodynamics and Drug Dosing Optimization
  • Clinical Decision Support Systems

Background:

  • Warfarin, a vitamin K antagonist, is widely used for stroke prevention in atrial fibrillation but poses challenges due to complex pharmacodynamics, often leading to suboptimal anticoagulation.
  • Achieving and maintaining the target International Normalized Ratio (INR) range (2.0-3.0) is crucial for warfarin efficacy and safety, yet difficult to achieve consistently in clinical practice.

Purpose of the Study:

  • To develop and validate a deep reinforcement learning (DRL) model for optimizing warfarin dosing to maximize time in the therapeutic INR range (TTR).
  • To assess the DRL model's effectiveness in improving clinical outcomes, specifically reducing the composite endpoint of stroke, systemic embolism, or major hemorrhage.

Main Methods:

  • A novel semi-Markov decision process formulation of the Batch-Constrained deep Q-learning algorithm was employed to create the DRL model.
  • The model was trained on data from 22,502 warfarin-treated patients across three major clinical trials (ENGAGE AF-TIMI 48, ARISTOTLE, ROCKET AF).
  • External validation was performed using data from 5730 warfarin-treated patients in the RE-LY trial, comparing algorithm-consistent dosing with TTR and clinical outcomes.

Main Results:

  • External validation demonstrated a significant positive association between center-level algorithm-consistent dosing and TTR (R² = 0.56).
  • A 10% increase in algorithm-consistent dosing correlated with a 6.78% improvement in TTR and an 11% reduction in the composite clinical outcome.
  • The DRL algorithm's performance was comparable to a rule-based clinical algorithm, indicating its robustness and potential for clinical application.

Conclusions:

  • A deep reinforcement learning algorithm can effectively optimize warfarin dosing to improve time in the therapeutic INR range for patients with atrial fibrillation.
  • Implementing a digital clinical decision support system based on this DRL algorithm holds promise for enhancing warfarin management and improving patient outcomes globally.